π DNB Anaesthesiology Β· June 2025
10 questions Β· 100 marks Β· Model answers with cited sources, key points, exam tips & extra-marks content.
Q1
a) What are the different methods to assess pain in a pediatric patient? [6] b) Describe any one score for post operative pain assessment in the pediatric patient. [4]
Γ
Model Answer
Part A
Methods of paediatric pain assessment
Pain assessment in children must be age- and development-appropriate. The three broad approaches are self-report, behavioural (observational) and physiological β the 'gold standard' is self-report where the child is developmentally able.
The three approaches
- 1. SELF-REPORT (gold standard, for developmentally able children, usually β₯4β7 years): Faces Pain ScaleβRevised / Wong-Baker FACES, visual analogue scale (VAS), numerical rating scale (NRS, older children), and the Poker Chip / 'pieces of hurt' tool.
- 2. BEHAVIOURAL / OBSERVATIONAL (for pre-verbal, non-verbal, cognitively impaired or unco-operative children): observe facial expression, cry, body movement, posture, consolability, leg tone β used in FLACC, CHEOPS, CRIES scales.
- 3. PHYSIOLOGICAL (adjunct, non-specific): heart rate, blood pressure, respiratory rate, sweating, pupil size and (neonates) vagal tone/oxygen saturation changes β non-specific, so used to support behavioural scores, not alone.
- Composite scales (e.g. neonatal PIPP, CRIES) combine behavioural and physiological items β most useful in neonates.
- Assessment must be repeated (before and after analgesia), and account for the child's developmental age, cultural context and the presence of parents.
Part B
FLACC scale β a postoperative paediatric pain score
The FLACC scale is a validated behavioural (observational) pain-assessment tool for children ~2 monthsβ7 years (and non-verbal/cognitively impaired children) β ideal for postoperative pain when self-report is not possible.
Five categories (each scored 0, 1 or 2 β total 0β10)
- F β Face: 0 = no expression/smile; 1 = occasional grimace/frown, withdrawn; 2 = frequent/constant frown, clenched jaw, quivering chin.
- L β Legs: 0 = relaxed; 1 = uneasy/restless/tense; 2 = kicking or legs drawn up.
- A β Activity: 0 = lying quietly, moves easily; 1 = squirming, tense, shifting; 2 = arched, rigid or jerking.
- C β Cry: 0 = no cry; 1 = moans/whimpers, occasional complaint; 2 = crying steadily, screams/sobs, frequent complaints.
- C β Consolability: 0 = content, relaxed; 1 = reassured by touching/talking, distractible; 2 = difficult to console or comfort.
- Interpretation: 0 = relaxed/comfortable; 1β3 = mild discomfort; 4β6 = moderate pain; 7β10 = severe pain/discomfort β titrate analgesia and reassess.
β
Key Points
- Paediatric pain is assessed by self-report (gold standard where able), behavioural/observational scales (pre-verbal/non-verbal), and physiological indices (non-specific adjunct).
- Match the tool to developmental age: FACES/VAS/NRS for older children; FLACC/CHEOPS/CRIES for infants and non-verbal children.
- FLACC (Face, Legs, Activity, Cry, Consolability; each 0β2, total 0β10) is a validated postoperative behavioural score for young/non-verbal children.
π Clinical Pearls
- Self-report is the gold standard whenever the child can do it β but for the pre-verbal, sedated, ventilated or cognitively-impaired child you MUST switch to a behavioural scale like FLACC.
- Physiological signs (tachycardia, hypertension) are non-specific β fever, hypovolaemia, hypoxia and anxiety all raise them β so never assess a child's pain on vital signs alone.
- Always reassess AFTER an analgesic intervention: a pain score is only useful as a repeated measure guiding titration, not a one-off number.
- Involve the parents β parental presence and their report of the child's behaviour hugely improve the accuracy of assessment in young children.
β Common Mistakes to Avoid
- Using a self-report scale (VAS/NRS) in a child too young to understand it, instead of a behavioural scale.
- Relying on heart rate/blood pressure alone to judge pain (non-specific).
- Assessing pain only once rather than repeatedly before and after analgesia.
π‘ Examiner Tip
For part (a), give the three-approach framework (self-report/behavioural/physiological) with named tools and the age-appropriateness principle. For part (b), take FLACC and lay out all five categories with the 0β10 interpretation.
π Sources & References
- CotΓ© & Lerman β A Practice of Anesthesia for Infants and Children (pain assessment).
- Merkel SI et al. The FLACC scale. Pediatr Nurs 1997.
- APA (Association of Paediatric Anaesthetists) β Good Practice in Postoperative and Procedural Pain Management.
- Gregory's Pediatric Anesthesia.
β Extra Marks Content
β Extra Theory Edge
- Neonatal-specific composite scales: PIPP (Premature Infant Pain Profile) and CRIES (Crying, Requires Oβ, Increased vitals, Expression, Sleeplessness) combine behavioural + physiological items.
- CHEOPS (Children's Hospital of Eastern Ontario Pain Scale) is another validated post-op behavioural tool (cry, facial, verbal, torso, touch, legs).
- The r-FLACC (revised) is validated specifically for children with cognitive impairment, incorporating individualised behaviours described by carers.
Q2
a) Continuous renal replacement therapy. [5] b) Use of magnesium in anaesthesia and ICU. [5]
Γ
Model Answer
Part A
Continuous Renal Replacement Therapy (CRRT)
CRRT is a slow, continuous (24-h) form of renal replacement/blood purification used in critically-ill, haemodynamically-unstable patients with acute kidney injury β removing solute and fluid gradually, which is far better tolerated than intermittent haemodialysis.
Principles & modes
- Solute is removed by DIFFUSION (dialysis β down a concentration gradient across a membrane, countercurrent dialysate) and/or CONVECTION (haemofiltration β 'solvent drag' as fluid is ultrafiltered across the membrane and replaced), plus ULTRAFILTRATION for fluid removal.
- Modes: SCUF (slow continuous ultrafiltration β fluid only), CVVH (continuous veno-venous haemoFILTRATION β convection), CVVHD (haemoDIALYSIS β diffusion), CVVHDF (haemoDIAFILTRATION β both). Access is via a double-lumen veno-venous catheter with a pump.
- Anticoagulation of the circuit: regional CITRATE (preferred β anticoagulates only the circuit, not the patient) or systemic heparin.
Indications & advantages
- Indications (AKI): refractory fluid overload/pulmonary oedema, severe hyperkalaemia, severe metabolic acidosis, uraemic complications (encephalopathy, pericarditis), and to make 'space' for nutrition/drugs; also some intoxications and (investigational) sepsis/cytokine removal.
- Advantages over intermittent HD in the ICU: better haemodynamic stability (slow fluid shifts), gradual osmolar change (avoids dialysis dysequilibrium, good in raised ICP/brain injury), precise fluid balance, and continuous solute control.
Part B
Uses of magnesium in anaesthesia and the ICU
Magnesium is a physiological calcium antagonist and NMDA-receptor antagonist with membrane-stabilising, vasodilator, bronchodilator and anticonvulsant properties β giving it many peri-operative and critical-care uses.
Clinical uses
- Obstetrics: seizure prophylaxis and treatment in severe pre-eclampsia/ECLAMPSIA (the drug of choice); also fetal neuroprotection and tocolysis.
- Cardiac: treatment of Torsades de pointes (drug of choice) and other arrhythmias; part of arrhythmia prophylaxis in cardiac surgery.
- Analgesia: NMDA antagonist β reduces postoperative pain and opioid requirement (adjunct in multimodal/opioid-free anaesthesia); attenuates opioid-induced hyperalgesia.
- Attenuation of the pressor response to laryngoscopy and of the catecholamine response (e.g. phaeochromocytoma).
- Respiratory: bronchodilator in severe/refractory acute asthma.
- Correction of hypomagnesaemia (common in ICU β associated with arrhythmias, hypokalaemia, hypocalcaemia).
- Others: adjunct to neuromuscular block (potentiates relaxants), tetanus, and controlled hypotension.
Toxicity (monitor)
- Progressive toxicity: loss of deep tendon reflexes (~5 mmol/L), respiratory depression, then cardiac conduction block/arrest at high levels; potentiation of neuromuscular block. Antidote: IV calcium gluconate.
β
Key Points
- CRRT is slow, continuous RRT for haemodynamically-unstable ICU patients with AKI; solute removal by diffusion (dialysis) and/or convection (filtration), with modes SCUF/CVVH/CVVHD/CVVHDF and citrate/heparin circuit anticoagulation.
- CRRT's advantage over intermittent HD is haemodynamic stability and gradual osmolar change (important in brain injury/raised ICP) with precise fluid control.
- Magnesium (Ca-antagonist + NMDA-antagonist): eclampsia seizure prophylaxis, Torsades, analgesic adjuvant, pressor-response attenuation, bronchodilation and correction of hypomagnesaemia β watch for toxicity (areflexia β respiratory/cardiac depression; antidote calcium).
π Clinical Pearls
- Regional CITRATE anticoagulation is now preferred for CRRT circuits: it anticoagulates only the extracorporeal blood (reversed by the patient's own metabolism), avoiding systemic bleeding risk β but watch for citrate accumulation in liver failure (metabolic alkalosis, high total:ionised calcium ratio).
- CRRT is specifically favoured in acute brain injury/raised ICP because the gradual solute shift avoids the cerebral oedema of rapid intermittent dialysis (dialysis dysequilibrium).
- Magnesium is the FIRST-LINE drug for eclamptic seizures AND for Torsades de pointes β two classic 'drug of choice' answers examiners love.
- CRRT and other renal replacement therapies REMOVE many drugs (including antibiotics) β dose adjustment and level monitoring are essential to avoid under-treating sepsis.
β Common Mistakes to Avoid
- Confusing the mechanisms β diffusion (dialysis, concentration gradient) vs convection (filtration, solvent drag) β and the corresponding modes.
- Forgetting citrate-accumulation risk in hepatic failure during citrate anticoagulation.
- Overlooking magnesium toxicity monitoring (reflexes) or forgetting calcium as the antidote.
π‘ Examiner Tip
For CRRT, define it, give the diffusion/convection principle, the modes, anticoagulation, indications and its haemodynamic advantage. For magnesium, list β₯5 distinct uses with the mechanism, and include toxicity + antidote.
π Sources & References
- Oh's Intensive Care Manual β Renal replacement therapy.
- KDIGO Clinical Practice Guideline for Acute Kidney Injury.
- Miller's Anesthesia, 9th Ed β Magnesium; renal failure & the ICU.
- Herroeder S et al. Magnesium β essentials for anesthesiologists. Anesthesiology 2011.
β Extra Marks Content
β Extra Theory Edge
- CRRT 'dose' is prescribed as effluent flow (~20β25 mL/kg/h per KDIGO); higher doses do not improve outcome (RENAL, ATN trials).
- Timing of RRT in AKI (early vs delayed) is debated β recent trials (STARRT-AKI) support waiting for a clear indication rather than pre-emptive early start.
- Magnesium therapeutic range in pre-eclampsia is 2β3.5 mmol/L (4β7 mEq/L); it also causes mild vasodilation/hypotension and potentiates non-depolarising neuromuscular block β reduce relaxant doses.
Q3
a) Describe acute kidney injury and its assessment in the critical care unit. [5] b) Discuss the management of 50-year-old admitted in ICU with flail chest. [5]
Γ
Model Answer
Part A
Acute Kidney Injury (AKI) β definition & assessment
AKI is an abrupt (hoursβdays) decline in renal function, defined and staged by the KDIGO criteria using serum creatinine and urine output.
KDIGO definition & staging
- Definition: rise in serum creatinine β₯26.5 Β΅mol/L (0.3 mg/dL) within 48 h, OR β₯1.5Γ baseline within 7 days, OR urine output <0.5 mL/kg/h for β₯6 h.
- Stage 1: creatinine 1.5β1.9Γ baseline (or +26.5 Β΅mol/L) / UO <0.5 mL/kg/h for 6β12 h.
- Stage 2: creatinine 2.0β2.9Γ baseline / UO <0.5 mL/kg/h for β₯12 h.
- Stage 3: creatinine β₯3Γ baseline (or β₯354 Β΅mol/L) or on RRT / UO <0.3 mL/kg/h for β₯24 h or anuria β₯12 h.
- (KDIGO unified the earlier RIFLE and AKIN criteria.)
Assessment in the ICU (find the cause: pre-renal / renal / post-renal)
- History/examination and volume status; identify nephrotoxins (contrast, aminoglycosides, NSAIDs), sepsis and hypoperfusion.
- Urine: output trend, urinalysis (casts, protein, blood), urine electrolytes/osmolality (fractional excretion of sodium β low in pre-renal, high in ATN).
- Blood: urea, creatinine, electrolytes (especially KβΊ), acid-base, and trend.
- Imaging: renal ultrasound to exclude OBSTRUCTION (post-renal) and assess size.
- Novel biomarkers: NGAL, cystatin C, KIM-1, TIMP-2Β·IGFBP7 (early tubular-stress markers).
Part B
Management of flail chest in the ICU
Flail chest = β₯3 contiguous ribs each fractured in β₯2 places, producing a free 'flail' segment that moves PARADOXICALLY (in on inspiration, out on expiration). The major problem is not the paradox itself but the underlying PULMONARY CONTUSION and pain-related hypoventilation.
Management principles
- ANALGESIA is the cornerstone: excellent pain relief allows deep breathing, coughing and physiotherapy, preventing atelectasis and pneumonia. THORACIC EPIDURAL analgesia is the gold standard; alternatives: paravertebral/erector-spinae/intercostal blocks, and multimodal systemic analgesia (opioids + paracetamol Β± ketamine).
- Respiratory support: humidified oxygen, aggressive chest physiotherapy and secretion clearance; NON-INVASIVE ventilation (CPAP/BiPAP) if adequate analgesia and no contraindication; invasive ventilation ('internal pneumatic splinting') for respiratory failure, severe contusion or associated injuries.
- Treat the underlying pulmonary contusion: judicious (not excessive) fluids to avoid worsening the contusion, lung-protective ventilation if ventilated.
- Monitor for and manage associated injuries: pneumothorax/haemothorax (chest drain), and other trauma; serial ABGs and imaging.
- SURGICAL RIB FIXATION (SSRF): increasingly indicated for severe flail chest / failure to wean / significantly displaced fractures β reduces ventilator days, ICU stay and pneumonia.
- Supportive ICU care: nutrition, VTE prophylaxis, and early mobilisation.
β
Key Points
- AKI is defined/staged by KDIGO using serum creatinine (β₯26.5 Β΅mol/L rise in 48 h or β₯1.5Γ baseline) and urine output (<0.5 mL/kg/h β₯6 h); assess by classifying pre-renal/renal/post-renal with urine indices, bloods and ultrasound.
- Flail chest management centres on ANALGESIA (thoracic epidural is gold standard) to enable breathing/physiotherapy, plus respiratory support (Oβ/NIV/invasive as needed) and treating the underlying pulmonary contusion.
- Surgical rib fixation is increasingly used for severe flail chest and reduces ventilator days and pneumonia.
π Clinical Pearls
- In flail chest the real enemy is the underlying PULMONARY CONTUSION and pain-limited breathing, not the paradoxical segment itself β that's why good analgesia (thoracic epidural) matters more than 'stabilising' the chest wall.
- Fluid management is a balancing act: under-resuscitation worsens shock/AKI, but over-resuscitation floods the contused lung β aim for judicious, targeted fluids.
- Urine output is the earliest bedside marker of AKI β oliguria often precedes the creatinine rise by hours, so a falling urine output in the ICU is an early warning.
- Fractional excretion of sodium (FENa <1% = pre-renal, >2% = ATN) helps distinguish reversible pre-renal AKI from established tubular injury β but is unreliable after diuretics.
β Common Mistakes to Avoid
- Focusing on the paradoxical chest movement and neglecting the pulmonary contusion and analgesia that actually determine outcome.
- Over-transfusing/over-filling the flail-chest patient and worsening the contusion.
- Using only serum creatinine to diagnose AKI and ignoring urine output (the earlier, more sensitive marker).
π‘ Examiner Tip
For AKI, quote the KDIGO creatinine/urine-output criteria and staging and the pre-/renal/post-renal assessment. For flail chest, lead with analgesia (thoracic epidural), then respiratory support and treating the contusion, and mention surgical fixation.
π Sources & References
- KDIGO Clinical Practice Guideline for Acute Kidney Injury.
- Oh's Intensive Care Manual β Acute kidney injury; chest trauma.
- ATLS 10th Edition β Thoracic trauma.
- Miller's Anesthesia, 9th Ed β Trauma; the critically ill patient.
β Extra Marks Content
β Extra Theory Edge
- The evolution of AKI definitions: RIFLE (Risk/Injury/Failure/Loss/ESRD) β AKIN β the unified KDIGO staging used today.
- Pulmonary contusion typically WORSENS over the first 24β48 h (radiographic and gas-exchange deterioration) β anticipate delayed respiratory failure in flail chest.
- Indications for surgical rib fixation include flail chest with respiratory failure, failure to wean from ventilation, significantly displaced fractures and severe chest-wall deformity/pain.
Q4
a) Role of simulators in anesthesia training. [5] b) Depth of analgesia monitoring. [5]
Γ
Model Answer
Part A
Role of simulators in anaesthesia training
Simulation is an educational technique that recreates clinical situations in a safe, controlled environment for training, assessment and practice β increasingly central to anaesthesia education because anaesthesia is a high-stakes, procedure- and crisis-rich specialty.
Roles, types & benefits
- Types: part-task trainers (airway/IV/central-line/regional manikins), full-body high-fidelity computerised patient simulators, screen-based/virtual-reality trainers, and standardised (simulated) patients for communication.
- Skills taught: technical/procedural skills (intubation, fibreoptic, central lines, regional blocks), and crucially NON-TECHNICAL skills β the ANTS domains (situation awareness, decision-making, task management, teamwork/communication) via Crisis Resource Management (CRM) training.
- Rare emergencies: safe, repeated rehearsal of critical incidents that are too rare/dangerous to learn on patients β malignant hyperthermia, anaphylaxis, 'can't intubate can't oxygenate', local-anaesthetic toxicity, cardiac arrest.
- Benefits: no risk to real patients ('first, do no harm to the learner's patient'), deliberate practice to competence, immediate structured DEBRIEFING (where most learning occurs), objective assessment, and team/system testing (in-situ simulation reveals latent errors).
- Also used for assessment (OSCEs), certification/revalidation and research; limitation β cost, fidelity gap and need for trained facilitators.
Part B
Depth of analgesia (nociception) monitoring
Depth-of-analgesia (antinociception) monitors aim to quantify the balance between the noxious surgical stimulus and the antinociceptive (analgesic) effect β helping to titrate intra-operative analgesia objectively, since analgesia (unlike hypnosis, monitored by BIS) has no long-established monitor.
Available monitors / methods
- Surgical Pleth Index (SPI / SSI): derived from photoplethysmographic pulse-wave amplitude and heart-rate interval β a low SPI suggests adequate analgesia.
- Analgesia Nociception Index (ANI): based on heart-rate variability (high-frequency parasympathetic tone) β high ANI = good analgesia/parasympathetic dominance.
- Nociception Level (NOL) index: a multi-parameter index (photoplethysmography, skin conductance, temperature, accelerometry) processed by an algorithm.
- Pupillometry: pupillary dilatation reflex to a noxious stimulus reflects the analgesic state.
- Skin conductance / sweating response and traditional clinical/autonomic surrogates (heart rate, blood pressure, lacrimation, sweating, movement) β non-specific.
- Uses: guide opioid titration (avoid under- and over-dosing), part of opioid-free/opioid-sparing anaesthesia, and reduce postoperative pain/opioid consumption; still evolving evidence for hard outcomes.
β
Key Points
- Simulation trains technical skills AND non-technical skills (ANTS/CRM β situation awareness, decision-making, teamwork), and lets trainees rehearse rare crises (MH, anaphylaxis, CICO) safely; the DEBRIEF is where most learning happens.
- Depth-of-analgesia (nociception) monitors quantify the nociceptionβantinociception balance to titrate analgesia objectively.
- Examples: Surgical Pleth Index (SPI), Analgesia Nociception Index (ANI, heart-rate variability), NOL index, and pupillometry β versus non-specific autonomic signs (HR/BP).
π Clinical Pearls
- In simulation, the DEBRIEF β not the scenario itself β is where the real learning occurs; a well-facilitated, non-judgemental debrief turns an experience into durable insight.
- Simulation shines for the crises you can't safely practise on patients: 'can't intubate, can't oxygenate', malignant hyperthermia, LA toxicity and anaphylaxis β muscle-memory drills that save lives.
- There is a monitor for hypnosis (BIS/entropy) but no gold-standard monitor for analgesia β nociception indices (SPI/ANI/NOL/pupillometry) are attempts to fill that gap, useful in opioid-free anaesthesia.
- A rising heart rate/blood pressure under anaesthesia is a crude, non-specific analgesia signal β nociception monitors add value precisely because these autonomic surrogates are unreliable (blunted by beta-blockers, confounded by hypovolaemia).
β Common Mistakes to Avoid
- Describing simulation as only for technical/procedural skills and omitting non-technical skills (CRM/ANTS) and the central role of debriefing.
- Confusing depth-of-ANALGESIA (nociception) monitors with depth-of-HYPNOSIS monitors (BIS/entropy) β they measure different components of the anaesthesia triad.
- Overstating the evidence β nociception monitors help titration but robust outcome data are still limited.
π‘ Examiner Tip
For simulation, cover types, technical + non-technical (CRM) skills, rare-crisis rehearsal, patient safety and debriefing. For analgesia monitoring, name the specific indices (SPI, ANI, NOL, pupillometry) and their basis, and note there is no gold standard.
π Sources & References
- Miller's Anesthesia, 9th Ed β Simulation in anesthesia; monitoring.
- Gaba DM β The future vision of simulation in healthcare.
- Flin R, Patey R β Anaesthetists' Non-Technical Skills (ANTS).
- Gruenewald M, Ilies C β Monitoring the nociceptionβantinociception balance. Best Pract Res Clin Anaesthesiol 2013.
β Extra Marks Content
β Extra Theory Edge
- Fidelity: low/part-task (skills), medium, and high-fidelity (full-body computerised) simulators; 'in-situ' simulation in the real workplace uncovers latent system/latent-threat errors.
- Kirkpatrick levels (reaction β learning β behaviour β results) frame how simulation training is evaluated.
- Combining a hypnosis monitor (BIS) with a nociception monitor (SPI/ANI/NOL) allows separate titration of the two main anaesthetic components β the practical realisation of the anaesthesia triad.
Q5
a) Programmed intermittent epidural bolus technique. [5] b) Remimazolam. [5]
Γ
Model Answer
Part A
Programmed Intermittent Epidural Bolus (PIEB)
PIEB is a mode of maintaining epidural analgesia (chiefly for labour) in which the pump delivers fixed-volume boluses of dilute local-anaesthetic/opioid solution at set time intervals (e.g. 5β10 mL every 30β60 min), instead of (or in addition to) a continuous infusion β usually combined with patient-controlled epidural boluses (PCEA).
Principle & advantages
- Principle: delivering the same hourly volume as a bolus at higher pressure produces MORE EXTENSIVE and UNIFORM spread of solution in the epidural space than a slow continuous infusion (better distribution through the multi-orifice catoheter and along the space).
- Advantages over continuous epidural infusion (CEI): better quality analgesia, more even/wider dermatomal spread, LESS local-anaesthetic consumption, LESS motor block (facilitates ambulation), fewer clinician top-ups/breakthrough pain, and higher maternal satisfaction.
- Typically combined with PCEA for breakthrough pain; parameters (bolus volume, interval, PCEA dose, lockout) are individualised.
- Considerations: the high-pressure bolus can rarely cause a higher block/hypotension β monitor; pump technology must support the mode.
Part B
Remimazolam
Remimazolam is a novel ULTRA-SHORT-ACTING benzodiazepine β a GABA-A receptor agonist β designed as a 'soft drug': it is rapidly metabolised by tissue (carboxyl)esterases to an inactive metabolite (CNS7054), giving a fast onset and, crucially, an ORGAN-INDEPENDENT, context-insensitive rapid offset.
Properties, uses & reversal
- Pharmacology: rapid onset (1β3 min), short duration, and NO accumulation on infusion (organ-independent ester metabolism, like remifentanil) β predictable, quick recovery.
- Haemodynamic stability: causes LESS hypotension and cardiorespiratory depression than propofol β attractive in the elderly and haemodynamically fragile.
- REVERSIBLE by FLUMAZENIL (a benzodiazepine antagonist) β a unique safety advantage over propofol.
- Uses: procedural SEDATION (endoscopy, bronchoscopy, cardiology), induction and maintenance of general ANAESTHESIA, and ICU sedation; useful where haemodynamic stability or reversibility is desirable.
- Advantages: rapid recovery, cardiovascular stability, reversibility, no injection pain (unlike propofol) and low PONV.
- Limitations: benzodiazepine class effects (limited analgesia β needs an opioid; theoretical delirium/tolerance concerns), cost, and less long-term outcome data.
β
Key Points
- PIEB delivers timed fixed-volume epidural boluses (vs a continuous infusion), giving wider, more uniform spread, better analgesia, LESS local-anaesthetic use and LESS motor block β ideal for ambulatory labour analgesia, usually with PCEA.
- Remimazolam is an ultra-short-acting benzodiazepine (GABA-A agonist) metabolised by tissue esterases β rapid, organ-independent, non-accumulating offset.
- Remimazolam causes less haemodynamic depression than propofol and is REVERSIBLE with flumazenil β used for procedural sedation, GA and ICU sedation.
π Clinical Pearls
- The magic of PIEB is that the SAME hourly dose delivered as a high-pressure bolus spreads better than a trickle infusion β better analgesia with LESS drug and LESS motor block.
- Remimazolam is the 'remifentanil of benzodiazepines' β ester-metabolised, non-accumulating, context-insensitive offset β so infusions wake up quickly regardless of duration.
- Remimazolam's two standout safety features are cardiovascular stability (great for the frail/elderly and cardiac patients) and REVERSIBILITY with flumazenil β neither of which propofol offers.
- Remimazolam provides sedation/hypnosis but NO analgesia (a benzodiazepine) β always pair it with an analgesic/opioid for painful procedures.
β Common Mistakes to Avoid
- Describing PIEB as just a faster continuous infusion β the key is the intermittent high-pressure bolus giving superior spread and less motor block.
- Forgetting that remimazolam is reversible with flumazenil and that it is metabolised by esterases (organ-independent), not the liver.
- Expecting analgesia from remimazolam (it is a pure sedative-hypnotic).
π‘ Examiner Tip
For PIEB, contrast it with continuous infusion and list the advantages (spread, less LA, less motor block, satisfaction). For remimazolam, emphasise ester metabolism/organ-independent offset, haemodynamic stability and flumazenil reversibility.
π Sources & References
- Chestnut's Obstetric Anesthesia, 6th Ed β Maintenance of labour epidural analgesia (PIEB).
- Miller's Anesthesia, 9th Ed β Intravenous anesthetics (novel agents).
- Wiltshire HR et al. / Kilpatrick GJ β Remimazolam pharmacology.
- Sng BL, Sia ATH β PIEB for labour analgesia (systematic reviews).
β Extra Marks Content
β Extra Theory Edge
- PIEB pump parameters interact: larger boluses at longer intervals generally give better spread than small frequent boluses; optimum is an area of active research.
- Remimazolam besylate was approved (Japan/US/EU, ~2020) initially for procedural sedation and (Japan) general anaesthesia; it shows promise for ICU sedation with rapid neurological assessment.
- Because remimazolam is ester-metabolised, it (like remifentanil and atracurium) is attractive in hepatic/renal impairment where organ-dependent drugs accumulate.
Q6
a) What is ventilator associated pneumonia (VAP)? [2] b) How can it be prevented? [4] c) Discuss the management of VAP. [4]
Γ
Model Answer
Definition
Ventilator-Associated Pneumonia (VAP) β definition [2]
VAP is a hospital-acquired pneumonia developing >48 hours after endotracheal intubation and mechanical ventilation, where the infection was neither present nor incubating at the time of intubation. Diagnosis is suggested by a new/progressive chest-X-ray infiltrate PLUS at least two of: fever/hypothermia, leucocytosis/leucopenia, purulent tracheal secretions, and worsening oxygenation β with microbiological confirmation from tracheal aspirate/BAL. Early-onset VAP (β€4 days) is usually due to more sensitive organisms; late-onset (β₯5 days) to multidrug-resistant organisms (Pseudomonas, MRSA, Acinetobacter).
Prevention
Prevention β the VAP care bundle [4]
- Head-of-bed ELEVATION to 30β45Β° (semi-recumbent) to reduce aspiration of gastric/oropharyngeal contents.
- Daily SEDATION HOLDS ('sedation vacation') and assessment of readiness to WEAN/EXTUBATE β shorter ventilation = less VAP.
- Oral care with chlorhexidine; subglottic secretion drainage (special ETTs) and maintaining ETT cuff pressure ~20β30 cmHβO to limit micro-aspiration.
- Prefer ORAL over nasal intubation (reduces sinusitis); avoid unnecessary re-intubation; use non-invasive ventilation where possible.
- Peptic ulcer and DVT prophylaxis (bundle components), hand hygiene and infection-control measures, and avoiding unnecessary ventilator-circuit changes.
- Minimise the duration of ventilation overall β the single most effective preventive strategy.
Management
Management of VAP [4]
- Obtain cultures FIRST (tracheal aspirate/BAL, blood cultures) then start EMPIRICAL broad-spectrum antibiotics promptly β do not delay treatment for cultures.
- Empirical choice guided by early vs late onset and local antibiogram/resistance patterns: cover Pseudomonas and, if MDR risk (late-onset, prior antibiotics, MRSA prevalence), add MRSA cover β e.g. an antipseudomonal Ξ²-lactam (piperacillin-tazobactam/meropenem/cefepime) Β± an aminoglycoside/fluoroquinolone Β± vancomycin/linezolid.
- DE-ESCALATE antibiotics once culture and sensitivity return; treat for a SHORT course (~7 days) if responding (equal outcomes to longer courses, less resistance).
- Supportive care: optimise oxygenation/lung-protective ventilation, physiotherapy and secretion clearance, source control, haemodynamic support and nutrition.
- Monitor response (clinical, gas exchange, inflammatory markers/CPIS); re-evaluate and broaden/change if not improving; treat complications (empyema, ARDS).
β
Key Points
- VAP = pneumonia >48 h after intubation (new infiltrate + clinical/microbiological features); early-onset (β€4 days, sensitive organisms) vs late-onset (β₯5 days, MDR organisms).
- Prevention = the VAP bundle: 30β45Β° head-up, daily sedation holds and weaning assessment, oral chlorhexidine, subglottic suction/cuff-pressure control, oral intubation, and minimising ventilation duration.
- Management: cultures then prompt empirical broad-spectrum antibiotics (cover Pseudomonas Β± MRSA per onset/local resistance), DE-ESCALATE on sensitivities, treat ~7 days, plus supportive care.
π Clinical Pearls
- The most powerful VAP-prevention measure is simply getting the patient OFF the ventilator sooner β daily sedation holds + spontaneous-breathing trials reduce ventilator days and therefore VAP.
- Take cultures but do NOT wait for them to start antibiotics β early appropriate empirical therapy improves survival; you refine/de-escalate later.
- Short-course antibiotics (~7 days) are as effective as longer courses for most VAP and reduce resistance and C. difficile β 'shorter is better' when the patient is responding.
- Late-onset VAP (β₯5 days) and prior antibiotic exposure flag MDR organisms (Pseudomonas, MRSA, Acinetobacter) β broaden empirical cover accordingly, then de-escalate.
β Common Mistakes to Avoid
- Delaying empirical antibiotics while waiting for culture results (worsens outcome).
- Failing to de-escalate and treating for prolonged courses, driving resistance.
- Ignoring the bundle (head-up position, sedation holds) which prevents VAP in the first place.
π‘ Examiner Tip
Give the crisp 2-4-4 structure: a precise definition (>48 h, criteria, early vs late), the VAP bundle for prevention, and a management sequence (cultures β early empirical broad-spectrum β de-escalate β short course + supportive care).
π Sources & References
- IDSA/ATS Guidelines for Management of Hospital-Acquired and Ventilator-Associated Pneumonia (2016).
- Oh's Intensive Care Manual β Nosocomial infection / VAP.
- Surviving Sepsis & institutional VAP-prevention bundles.
- Miller's Anesthesia, 9th Ed β Critical care & nosocomial infection.
β Extra Marks Content
β Extra Theory Edge
- The Clinical Pulmonary Infection Score (CPIS, using temperature, WCC, secretions, oxygenation, CXR and culture) aids diagnosis and guides duration, though its accuracy is debated.
- VAP is a subset of the newer surveillance concept 'ventilator-associated events (VAE)', which captures ventilator-associated conditions more objectively.
- Selective oral/digestive decontamination (SOD/SDD) reduces VAP in some ICUs but is not universally adopted owing to antimicrobial-resistance concerns.
Q7
a) WHO ladder for cancer pain management. [5] b) qSOFA score. [5]
Γ
Model Answer
Part A
WHO analgesic ladder for cancer pain
The WHO analgesic ladder (1986) is a stepwise framework for cancer-pain management, escalating analgesia according to pain severity, with the principle of giving analgesia 'by the mouth, by the clock, by the ladder, for the individual, with attention to detail'.
The three steps (Β± a fourth)
- Step 1 β MILD pain: NON-OPIOID Β± ADJUVANT. Paracetamol and/or an NSAID, plus adjuvants.
- Step 2 β MILD-to-MODERATE pain: WEAK OPIOID (codeine, tramadol, low-dose oral morphine) + non-opioid Β± adjuvant.
- Step 3 β MODERATE-to-SEVERE pain: STRONG OPIOID (morphine, oxycodone, fentanyl, hydromorphone) + non-opioid Β± adjuvant.
- Step 4 (added in practice): INTERVENTIONAL / invasive techniques β nerve blocks, neuraxial (intrathecal/epidural) analgesia, neurolytic blocks (e.g. coeliac plexus), spinal-cord stimulation β for pain refractory to Step 3.
- Adjuvants (at every step): antidepressants (amitriptyline, duloxetine) and anticonvulsants (gabapentin, pregabalin) for neuropathic pain, corticosteroids, bisphosphonates for bony pain, antispasmodics, and management of side-effects (laxatives, antiemetics).
Key principles
- By the CLOCK (regular dosing, not PRN) with breakthrough (rescue) doses available; by the MOUTH (oral where possible); individualised titration; and anticipation/treatment of side-effects (constipation, nausea).
Part B
qSOFA (quick Sequential Organ Failure Assessment) score
qSOFA is a rapid, bedside screening tool (introduced with the Sepsis-3 definitions, 2016) to identify patients with suspected infection who are at increased risk of poor outcome (death/prolonged ICU stay) β usable OUTSIDE the ICU without laboratory tests.
The three criteria (1 point each; score β₯2 = high risk)
- Respiratory rate β₯22 breaths/min.
- Altered mentation (Glasgow Coma Scale <15).
- Systolic blood pressure β€100 mmHg.
- Interpretation: a qSOFA β₯2 in a patient with suspected infection identifies those at greater risk of sepsis-related death and prompts escalation (closer monitoring, investigation for organ dysfunction, and full SOFA assessment).
Context & limitations
- Sepsis-3: sepsis = life-threatening organ dysfunction (a rise in SOFA β₯2) due to a dysregulated host response to infection; septic shock = sepsis with vasopressor-requiring hypotension AND lactate >2 mmol/L despite fluids.
- qSOFA is a prompt/screen, NOT a diagnosis of sepsis and not part of the definition; it has good specificity but limited sensitivity β a low qSOFA does not exclude sepsis.
- Newer guidance (Surviving Sepsis 2021) does NOT recommend qSOFA as the sole screening tool β use alongside NEWS2/SIRS and clinical judgement.
β
Key Points
- WHO ladder: Step 1 non-opioid Β± adjuvant β Step 2 weak opioid β Step 3 strong opioid (each Β± non-opioid Β± adjuvant), with a Step 4 of interventional techniques; principles = by mouth, by the clock, by the ladder, individualised.
- qSOFA (RR β₯22, altered mentation GCS <15, SBP β€100) β a rapid non-laboratory bedside screen; β₯2 points flags high risk in suspected infection.
- qSOFA is a prompt to escalate, not a diagnosis of sepsis; Sepsis-3 defines sepsis as organ dysfunction (SOFA rise β₯2) from a dysregulated host response to infection.
π Clinical Pearls
- Give cancer-pain analgesia 'by the clock' (regular), not just PRN, with breakthrough rescue doses β chasing established pain with PRN dosing gives poor control.
- Always co-prescribe a LAXATIVE with strong opioids for cancer pain β opioid-induced constipation is universal and, unlike nausea, does NOT develop tolerance.
- qSOFA needs NO blood tests β three bedside signs (fast breathing, confusion, low BP) β making it a rapid ward screen; but a normal qSOFA does NOT rule out sepsis (low sensitivity).
- Neuropathic cancer pain responds poorly to opioids alone β reach early for adjuvants (amitriptyline, gabapentin/pregabalin, steroids) at any step of the ladder.
β Common Mistakes to Avoid
- Prescribing opioids PRN instead of regularly (by the clock) and forgetting breakthrough doses and laxatives.
- Treating qSOFA as a diagnostic definition of sepsis rather than a risk-stratification prompt, or relying on it alone (low sensitivity).
- Omitting adjuvants for neuropathic/bony cancer pain and escalating opioids ineffectively.
π‘ Examiner Tip
Draw the three-step ladder (add Step 4 interventional) with the 'by mouth/by the clock/by the ladder/for the individual' principles and adjuvants. For qSOFA, give the three criteria and the β₯2 cut-off, and place it correctly within Sepsis-3.
π Sources & References
- WHO β Cancer Pain Relief and the analgesic ladder.
- Singer M et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016.
- Surviving Sepsis Campaign Guidelines 2021.
- Miller's Anesthesia, 9th Ed β Cancer pain; sepsis.
β Extra Marks Content
β Extra Theory Edge
- The WHO ladder is being modernised into a bidirectional/'lift' concept β for severe or acute-on-chronic cancer pain you can start high (strong opioid) and step down, and interventional techniques can be used earlier.
- The full SOFA score grades dysfunction in six systems (respiration/PaOβ:FiOβ, coagulation/platelets, liver/bilirubin, cardiovascular/MAP-vasopressors, CNS/GCS, renal/creatinine-urine output).
- Opioid conversion and equianalgesic dosing (e.g. oral:IV morphine 3:1; morphine to oxycodone ~1.5:1) are essential practical skills when climbing the ladder.
Q8
a) What is EXIT procedure? [3] b) How would you manage anaesthesia for intrauterine fetal surgery? [7]
Γ
Model Answer
Part A
EXIT procedure
EXIT = Ex-Utero Intrapartum Treatment. It is a specialised procedure performed at (or near) delivery in which the fetus is PARTIALLY delivered (usually head and shoulders) through a hysterotomy while UTEROPLACENTAL circulation and gas exchange are DELIBERATELY MAINTAINED β buying time to secure the fetal airway or perform a procedure BEFORE the cord is clamped.
Indications
- Anticipated difficult/obstructed fetal airway: large neck masses (cervical teratoma, lymphangioma), congenital high airway obstruction syndrome (CHAOS), severe micrognathia.
- To secure the airway (intubation/bronchoscopy/tracheostomy) or resect a mass, or place the neonate on ECMO (e.g. severe congenital diaphragmatic hernia) β all while placental support continues.
- The key is maintaining UTERINE RELAXATION so placental gas exchange sustains the fetus during the intervention.
Part B
Anaesthesia for intrauterine (fetal) surgery
Fetal surgery (open, or EXIT, or fetoscopic) is unique: the anaesthetist cares for TWO patients simultaneously β the mother and the fetus β and the paramount requirement (for open/EXIT surgery) is profound UTERINE RELAXATION while preserving uteroplacental perfusion and providing fetal anaesthesia/analgesia and immobility.
Maternal management
- Full obstetric anaesthetic considerations: aspiration prophylaxis and RSI, LEFT uterine displacement, large-bore access, invasive monitoring for major open cases.
- GENERAL ANAESTHESIA with a HIGH concentration of a VOLATILE agent (e.g. 2β3 MAC sevoflurane/desflurane) is the classic technique for open/EXIT surgery because volatiles provide profound UTERINE RELAXATION (tocolysis) and cross the placenta to anaesthetise the fetus.
- Additional tocolysis if needed: magnesium, nitroglycerin, terbutaline; but deep volatile-induced hypotension must be treated to preserve placental perfusion (vasopressors, fluids).
- Maintain maternal normoxia, normocapnia and normotension for fetal wellbeing.
Fetal management
- Fetal anaesthesia/analgesia and IMMOBILITY: partly from placental transfer of the volatile agent, PLUS direct intramuscular fetal injection of an OPIOID (fentanyl), a MUSCLE RELAXANT (vecuronium/rocuronium) and an anticholinergic (atropine) given by the surgeon.
- Fetal monitoring: intra-operative fetal echocardiography (heart rate, contractility, filling), pulse oximetry; maintain fetal temperature and have resuscitation drugs/blood (warmed, irradiated, CMV-negative, cross-matched) ready.
- Amnioinfusion with warm fluid to maintain uterine volume and cord/placental perfusion; avoid fetal hypothermia and hypovolaemia.
Post-procedure (for EXIT: the transition)
- For EXIT: only AFTER the airway/procedure is secured is the cord clamped and the neonate fully delivered and handed to the neonatal team; then uterine tone must be RESTORED rapidly (turn off/down volatile, give oxytocin/uterotonics) to prevent postpartum haemorrhage from the relaxed uterus.
- Manage the risk of maternal haemorrhage (relaxed uterus) and preterm labour; postoperative tocolysis and analgesia.
β
Key Points
- EXIT (Ex-Utero Intrapartum Treatment) maintains uteroplacental circulation while the partially-delivered fetus's airway/procedure is secured BEFORE cord clamping β for airway-obstructing neck masses, CHAOS, or to institute ECMO.
- Fetal surgery = two patients; open/EXIT needs profound UTERINE RELAXATION (high-dose volatile Β± magnesium/GTN/terbutaline) while maintaining uteroplacental perfusion.
- Fetal anaesthesia/immobility comes from placental volatile transfer PLUS direct fetal IM opioid + relaxant + atropine; monitor with fetal echo; after EXIT, restore uterine tone (oxytocin) to prevent haemorrhage.
π Clinical Pearls
- The whole point of EXIT is that the placenta keeps oxygenating the baby β so the enemy is uterine CONTRACTION (which shears the placenta); you deliberately relax the uterus with high-dose volatile and only clamp the cord once the airway is secured.
- High-dose volatile is a double-edged sword: it relaxes the uterus AND drops maternal blood pressure β treat maternal hypotension aggressively, because placental perfusion (and thus the fetus) depends on it.
- The dangerous moment after EXIT/open fetal surgery is uterine ATONY from the deep volatile β have oxytocin/uterotonics ready and turn the volatile down promptly after cord clamping to prevent massive PPH.
- The fetus is given its OWN anaesthetic (IM fentanyl + relaxant + atropine) directly β never assume placental transfer alone provides adequate fetal analgesia and immobility.
β Common Mistakes to Avoid
- Forgetting that the aim is uterine RELAXATION (not the usual uterine tone) during the procedure, and then failing to restore tone afterwards (causing haemorrhage).
- Neglecting maternal hypotension from deep volatile, compromising placental perfusion.
- Assuming placental drug transfer alone anaesthetises the fetus and omitting direct fetal opioid/relaxant/atropine.
π‘ Examiner Tip
Define EXIT crisply (placental support maintained until airway secured). For fetal surgery, structure around two patients: maternal (GA + high volatile for uterine relaxation + preserve perfusion) and fetal (direct IM anaesthesia + monitoring), then the uterine-tone/haemorrhage transition.
π Sources & References
- Chestnut's Obstetric Anesthesia, 6th Ed β Anesthesia for fetal surgery & EXIT.
- Miller's Anesthesia, 9th Ed β Fetal surgery.
- CotΓ© & Lerman β Anesthesia for fetal and neonatal surgery.
- Ferschl M et al. Anesthesia for in-utero and EXIT procedures (reviews).
β Extra Marks Content
β Extra Theory Edge
- Three types of fetal intervention: minimally invasive/FETOSCOPIC (e.g. laser for twin-twin transfusion, needs less uterine relaxation, can be maternal neuraxial Β± sedation), OPEN fetal surgery (e.g. myelomeningocele repair β MOMS trial), and EXIT.
- The MOMS trial established open fetal repair of spina bifida (myelomeningocele) as beneficial, popularising open fetal surgery.
- Fetoscopic procedures may be done under maternal regional/local Β± sedation with lighter tocolysis, whereas open/EXIT surgery mandates general anaesthesia with deep volatile tocolysis.
Q9
a) Enumerate the causes of acute hepatic failure. [3] b) What are the principles of management of acute hepatic failure in the ICU? [7]
Γ
Model Answer
Part A
Causes of acute (fulminant) hepatic failure [3]
Acute liver failure (ALF) = the rapid development of hepatocellular dysfunction with COAGULOPATHY (INR β₯1.5) and hepatic ENCEPHALOPATHY in a patient WITHOUT pre-existing liver disease, within ~26 weeks of the first symptom.
Causes
- DRUGS/TOXINS: PARACETAMOL overdose (the commonest cause in the UK/US), idiosyncratic drug reactions (anti-TB drugs, antiepileptics, halothane, herbal remedies), and Amanita phalloides (mushroom) poisoning.
- VIRAL hepatitis: hepatitis A, B, E (and E is important in pregnancy), rarely others (herpes, CMV).
- VASCULAR/ischaemic: 'shock liver' (ischaemic hepatitis), Budd-Chiari syndrome, veno-occlusive disease.
- PREGNANCY-related: acute fatty liver of pregnancy, HELLP syndrome.
- METABOLIC/other: Wilson's disease, autoimmune hepatitis, malignant infiltration, sepsis, heat stroke.
Part B
Principles of ICU management of acute liver failure [7]
ALF is a multi-organ emergency; management is largely supportive in a specialist/transplant centre while treating the cause and watching for the two big killers β cerebral oedema/raised ICP and multi-organ failure β and assessing transplant candidacy.
System-based principles
- Treat the CAUSE: N-ACETYLCYSTEINE for paracetamol toxicity (and it improves outcome even in non-paracetamol ALF); antivirals, penicillin/silibinin for Amanita, delivery for pregnancy-related ALF.
- NEUROLOGICAL β cerebral oedema/raised ICP (the leading cause of death): nurse head-up 30Β°, avoid hypercapnia/hypoxia/hyponatraemia, treat raised ICP (hypertonic saline/mannitol), control seizures; lactulose/rifaximin for encephalopathy; consider ICP monitoring; hyperammonaemia management (Β± CRRT).
- CARDIOVASCULAR: hyperdynamic, vasodilated circulation β fluids then vasopressors (noradrenaline) to maintain MAP/cerebral perfusion; consider hydrocortisone for refractory shock.
- RESPIRATORY: protect the airway (intubate/ventilate if grade 3β4 encephalopathy), lung-protective ventilation, treat aspiration/ARDS.
- COAGULATION/HAEMATOLOGY: correct clotting only for active bleeding or before procedures (INR is a prognostic marker β don't blindly normalise it); vitamin K, platelets/products/fibrinogen as needed; stress-ulcer prophylaxis.
- RENAL/METABOLIC: monitor for AKI/hepatorenal syndrome; CRRT for AKI, fluid/acid-base/ammonia control; treat HYPOGLYCAEMIA (frequent glucose monitoring, dextrose infusion), and correct electrolytes (KβΊ, POβ, MgΒ²βΊ) and lactic acidosis.
- INFECTION: high risk of sepsis (immunoparesis) β low threshold for cultures and antibiotics/antifungals.
- PROGNOSIS & TRANSPLANT: apply prognostic criteria (KING'S COLLEGE criteria) and refer EARLY to a liver-transplant centre β transplantation may be life-saving; nutritional support and multidisciplinary care throughout.
β
Key Points
- ALF = coagulopathy (INR β₯1.5) + encephalopathy without pre-existing liver disease; commonest cause is PARACETAMOL, then viral, vascular (shock liver), pregnancy-related and metabolic.
- ICU management is supportive & system-based: treat the cause (N-acetylcysteine), control cerebral oedema/raised ICP (the main killer), support cardiovascular/respiratory/renal systems, correct hypoglycaemia and coagulopathy (only if bleeding), treat sepsis.
- Apply King's College criteria and refer EARLY to a transplant centre β transplantation can be life-saving.
π Clinical Pearls
- Give N-ACETYLCYSTEINE early β it is life-saving in paracetamol ALF and improves transplant-free survival even in NON-paracetamol acute liver failure.
- CEREBRAL OEDEMA/raised ICP is the leading cause of death in ALF β avoid the aggravators (hyponatraemia, hypercapnia, hypoxia, fever, high ammonia) and treat ICP actively; this is why airway control and CRRT (ammonia clearance) matter.
- Don't reflexively correct the INR with FFP β the INR is a key PROGNOSTIC marker guiding transplant listing (King's criteria), and correction is only indicated for active bleeding or before an invasive procedure.
- HYPOGLYCAEMIA is common and easily missed in the sedated/encephalopathic ALF patient β check glucose frequently and run a dextrose infusion.
β Common Mistakes to Avoid
- Correcting the INR routinely with FFP, masking a vital prognostic marker used for transplant listing.
- Under-treating cerebral oedema/raised ICP (the main cause of death) and ignoring its aggravators.
- Delaying referral to a transplant centre and delaying N-acetylcysteine.
π‘ Examiner Tip
Enumerate causes by category (drugs/toxins, viral, vascular, pregnancy, metabolic) β paracetamol first. Then give a SYSTEM-BASED management (cause/NAC β neuro/ICP β CVS β resp β coag β renal/glucose β sepsis β transplant referral). Mention King's College criteria.
π Sources & References
- Oh's Intensive Care Manual β Acute liver failure.
- EASL / AASLD Clinical Practice Guidelines on acute (fulminant) liver failure.
- Miller's Anesthesia, 9th Ed β Hepatic failure & critical care.
- O'Grady JG β King's College Hospital criteria for liver transplantation in ALF.
β Extra Marks Content
β Extra Theory Edge
- King's College criteria (paracetamol): arterial pH <7.30, OR the triad of INR >6.5 (PT >100 s) + creatinine >300 Β΅mol/L + grade 3β4 encephalopathy β predict poor outcome without transplant.
- Encephalopathy grading (West Haven IβIV) tracks severity; grade 3β4 mandates airway protection and ICP vigilance.
- Extracorporeal liver-support/albumin-dialysis systems (MARS) can bridge to transplant/recovery in selected patients, though outcome benefit is unproven.
Q10
a) What is complex regional pain syndrome? [5] b) Discuss the treatment of complex regional pain syndrome. [5]
Γ
Model Answer
Part A
Complex Regional Pain Syndrome (CRPS) β definition
CRPS is a chronic neuropathic pain condition, usually affecting a limb, in which the pain is DISPROPORTIONATE in magnitude and duration to the inciting event (often trauma/surgery/immobilisation), accompanied by sensory, autonomic (vasomotor/sudomotor), motor and trophic changes.
Types & clinical features (Budapest criteria)
- TYPE I (formerly Reflex Sympathetic Dystrophy): NO definable nerve injury.
- TYPE II (formerly Causalgia): associated with a defined PERIPHERAL NERVE injury.
- Diagnosis is CLINICAL (Budapest criteria): continuing disproportionate pain PLUS signs/symptoms in β₯3 (symptoms) and β₯2 (signs) of four categories:
- β’ Sensory: hyperalgesia, allodynia.
- β’ Vasomotor: temperature asymmetry, skin-colour changes/asymmetry.
- β’ Sudomotor/oedema: sweating changes, oedema.
- β’ Motor/trophic: reduced range of motion, weakness/tremor/dystonia, and trophic changes to hair/nail/skin.
- β¦with no other diagnosis better explaining the signs. There is no single confirmatory test (bone scan/thermography are supportive only).
Part B
Treatment of CRPS
Management is MULTIDISCIPLINARY, aiming at functional restoration, with early diagnosis and treatment giving the best outcome. A stepwise, multimodal approach combines rehabilitation, pharmacology, psychology and interventional techniques.
Multimodal, functionally-oriented treatment
- REHABILITATION (the cornerstone): physiotherapy and occupational therapy for graded mobilisation, desensitisation, and GRADED MOTOR IMAGERY / mirror therapy β restore function and prevent disuse contractures.
- PHARMACOLOGICAL: neuropathic agents β gabapentinoids (gabapentin/pregabalin) and tricyclics (amitriptyline)/duloxetine; simple analgesics/NSAIDs; short courses of corticosteroids (especially early, inflammatory phase); bisphosphonates (evidence for pain/bony changes); topical agents (lidocaine, capsaicin); ketamine (NMDA antagonist) infusions in refractory cases.
- PSYCHOLOGICAL: cognitive-behavioural therapy, addressing depression/anxiety/catastrophising and coping β essential in a chronic pain condition.
- INTERPENTIONAL: SYMPATHETIC blocks (e.g. stellate ganglion for upper limb, lumbar sympathetic for lower limb) for sympathetically-maintained pain; regional/IV regional blocks; and for refractory cases SPINAL CORD STIMULATION (good evidence) or intrathecal drug delivery.
- General: EARLY diagnosis and treatment, encourage limb USE, treat the whole patient; avoid unnecessary surgery/immobilisation which can worsen it.
β
Key Points
- CRPS is disproportionate chronic neuropathic pain (usually a limb) with sensory, vasomotor, sudomotor/oedema and motor/trophic changes; Type I (no nerve injury) vs Type II (defined nerve injury); diagnosed clinically by the Budapest criteria.
- Treatment is MULTIDISCIPLINARY and functionally-oriented: rehabilitation (graded mobilisation, mirror therapy) is the cornerstone, plus neuropathic pharmacology, psychology and interventional techniques.
- Sympathetic blocks and spinal-cord stimulation are used for sympathetically-maintained/refractory pain; early diagnosis and limb use give the best outcomes.
π Clinical Pearls
- CRPS is a CLINICAL diagnosis (Budapest criteria) β there is no confirmatory test; bone scans and thermography are only supportive, so don't wait for a 'positive test' before treating.
- The single most important treatment is RESTORING FUNCTION β graded physiotherapy, desensitisation and mirror/graded-motor-imagery therapy; encouraging use of the limb (not resting/immobilising it) is central.
- EARLY diagnosis and treatment dramatically improve outcome β delay leads to fixed trophic/dystonic changes; think of CRPS in any post-injury pain that is out of proportion.
- Sympathetic (stellate/lumbar) blocks are both diagnostic and therapeutic for the sympathetically-maintained subset, and spinal cord stimulation has the best evidence for refractory CRPS.
β Common Mistakes to Avoid
- Waiting for an investigation to 'confirm' CRPS instead of making the clinical (Budapest) diagnosis and starting early treatment.
- Immobilising/resting the limb (which worsens CRPS) rather than encouraging graded functional use.
- Relying on drugs alone and neglecting the multidisciplinary rehabilitation and psychological components.
π‘ Examiner Tip
Define CRPS with the Type I/II distinction and the Budapest-criteria categories (sensory/vasomotor/sudomotor/motor-trophic). For treatment, give the multidisciplinary framework β rehabilitation first, then pharmacology, psychology and interventional (sympathetic blocks, SCS).
π Sources & References
- Harden RN et al. Budapest diagnostic criteria for CRPS. Pain Med 2013.
- Miller's Anesthesia, 9th Ed β Chronic pain / CRPS.
- Royal College of Physicians β CRPS in adults: UK guidelines.
- Cousins & Bridenbaugh β Neural Blockade in Clinical Anesthesia and Pain Medicine.
β Extra Marks Content
β Extra Theory Edge
- Proposed mechanisms: peripheral and central sensitisation, neurogenic inflammation, autonomic dysfunction, and cortical reorganisation (the basis for mirror/graded-motor-imagery therapy).
- CRPS classically has 'warm' (acute, inflammatory, vasodilated) and 'cold' (chronic, dystrophic) phases β the phase influences whether sympathetic blocks and anti-inflammatory measures help.
- Spinal cord stimulation has the strongest evidence among interventional options for refractory CRPS, improving pain and quality of life in selected patients.